JNJ Jan 2025 160.000 put
| Previous Close | 4.5500 |
| Open | 4.0000 |
| Bid | 3.9500 |
| Ask | 4.1000 |
| Strike | 160.00 |
| Expire Date | 2025-01-17 |
| Day's Range | 4.0000 - 4.4000 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 5.13k |
PR NewswireNew data from TAR-200 Phase 2b SunRISe-1 study show 84 percent complete response rate in patients with high-risk non-muscle-invasive bladder cancer
Johnson & Johnson (NYSE:JNJ) announced today additional results from the pivotal Phase 2b SunRISe-1 study, supporting the safety and efficacy profile of investigational TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC). New data were featured in a late-breaking oral presentation at the European Society of Medical Oncology (ESMO) 2024 Congress (Abstract #LBA85).
Insider MonkeyIs Johnson & Johnson (JNJ) the Best Blue Chip Stock To Invest In According to Short Sellers?
We recently compiled a list of the 12 Best Blue Chip Stocks To Invest In According to Short Sellers. In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against the other blue chip stocks. “Investors Need a Reason to Buy” While economic data may be scarce, every […]
- PR Newswire
RYBREVANT® (amivantamab-vmjw) plus chemotherapy show 49 percent overall response rate in metastatic colorectal cancer
Johnson & Johnson (NYSE:JNJ) today announced new data from the Phase 1b/2 OrigAMI-1 study, which showed RYBREVANT® (amivantamab-vmjw) combined with chemotherapy (mFOLFOX6 [FOLFOX] or FOLFIRI) demonstrated promising rapid and durable antitumor activity in patients with RAS/BRAF wild-type (WT) metastatic colorectal cancer (mCRC) who have not previously received anti-epidermal growth factor receptor (EGFR) therapy. These data were presented in a mini-oral presentation at the European Society of Med
